arsenic trioxide has been researched along with Lymphoma, Mantle-Cell in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, L; Li, XY; Li, Y; Liu, X; Wang, X; Zhang, L | 1 |
| Kwong, YL; Lo, RK | 1 |
| Au, WY; Cheung, WW; Gill, H; Kwong, YL; Lee, EY | 1 |
| Chen, SJ; Cui, W; Fei, AM; Gressin, R; Hermine, O; Khochbin, S; Liu, YF; Mi, JQ; Miao, SC; Peng, LJ; Wang, J; Zhao, LL | 1 |
| Fei, AM; Liu, JJ; Mao, CM; Mi, JQ; Zhu, J | 1 |
| Chen, Z; Jung, HJ; McCarty, N | 1 |
| Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK | 1 |
1 trial(s) available for arsenic trioxide and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lymphoma, Mantle-Cell; Male; Oxides; Phosphorylation; Proteasome Endopeptidase Complex; Proteolysis; Retinoblastoma Protein; Transcription, Genetic; Ubiquitination | 2014 |
6 other study(ies) available for arsenic trioxide and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Tumor; Cell Survival; DNA (Cytosine-5-)-Methyltransferase 1; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oxides; Wnt Signaling Pathway | 2017 |
Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Humans; Lymphoma, Mantle-Cell; Middle Aged; Oxides; Positron-Emission Tomography; Recurrence; Salvage Therapy; Survival Analysis | 2014 |
Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bortezomib; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2015 |
[Effect of arsenic trioxide on induction of apoptosis in MCL cell line and its possible mechanisms].
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mitochondria; Oxides | 2010 |
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines | 2012 |
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin | 2002 |